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Objectives. To perform a quantitative analysis of the vascular endothelial growth factor (VEGF) gene transcription in the skin of
ischemic legs and provide information for VEGF in the pathogenesis in critical limb ischemia (CLI). Methods. Skin biopsies were
obtained from 40 patients with CLI. Control samples came from 44 patients with chronic venous disease. VEGF gene expression
was analysed using quantitative polymerase chain reaction. Results. Patients with CLI had higher skin VEGF expression than
control group (RQ: 1.3 ± 0.1 versus 1, P = 0.04). Conclusions. We found an association between ischemic skin and an elevated
VEGF expression in legs from patients with CLI. These data support that the mechanism for VEGF upregulation in hypoxia
conditions is intact and acts appropriately in the ischaemic limbs from patients with CLI.
1.Introduction
Angiogenesis has been recently involved in the onset and
progression of atherosclerosis. The vascular endothelial
growth factor (VEGF) is considered a key regulator of an-
giogenesis. Several researches have demonstrated hypoxia as
the major factor in VEGF upregulation [1]. Its expression is
dramatically induced by low oxygen tension in endothelial
cells [2]. VEGF increases vascular permeability and induces
the migration and proliferation of endothelial cells [3]. It has
been proved that VEGF promotes an increase in microvessel
density and proliferation of vasa vasorum in atherosclerotic
plaques [4].
Critical limb ischemia (CLI) is the most severe clinical
manifestation of peripheral artery disease (PAD). Its World
incidence has been estimated to be 500 to 800 per million
inhabitants per year [5]. Without timely diagnosis and re-
vascularization, patients with CLI are at risk of devastating
complications including loss of limb and life.
Therapeuticangiogenesishasbeenassessedasanalterna-
tivetreatmentforCLIbeforetheamputation.Thereby,VEGF
is one of the most common growth factors used in ther-
apeutic angiogenesis treatment protocols. Disappointingly,
the results arose from the clinical trials in therapeutic
angiogenesis are not consistent because some of them
have not shown a clear eﬀect of this treatment [6]. A
likely explanation for these results may lie in the limited
knowledge about the complex pathogenesis of CLI and the
exact mechanism of action understanding of the therapeutic
angiogenesis factors we dispose so far.
Ontheotherhand,recentreportshaverecentlysuggested
serum VEGF levels to be an indicator of the severity of PAD
[7]. CLI is characterized by chronically hypoxic conditions
in muscle and epithelial tissues that last for weeks or
even months. This hypoxic environment would justify the
increased expression of VEGF in these CLI patients. So,
whether or not the concentration of VEGF is shown elevated
in the CLI patient tissues, the use of any means to increase
the levels of VEGF as a CLI therapy should be questioned.
Wehypothesizeaboutthepossibilitythatskininischemic
limbs in patients with CLI, in which hypoxia conditions are
critical, could be a source of VEGF. The aim of the current
paper is to perform a quantitative analysis of the VEGF gene
transcription in the skin of ischemic legs and to provide
information on VEGF expression in the pathogenesis of
CLI.2 International Journal of Vascular Medicine
Table 1: Clinical and demographic characteristics of CLI and control patients.
CLI (N = 40) Control (N = 44)
Median age 65.7 ±9.44 7 .2 ±9.9
Males (%) 29 (73.7) 26 (60.1)
Hypertension (%) 34 (84.6) 2 (4.5)
Diabetes mellitus (%) 23 (57) 0 (0)
Dyslipidemia (%) 18 (45) 0 (0)
Acute myocardial Infarction (%) 17 (42.1) 0 (0)
Stroke (%) 4 (10.3) 0 (0)
Renal failure (%) 2 (5.3) 0 (0)
Smoker (%) 25 (63) 2 (4.5)
2. Methods
2.1. Patients. 84 subjects were included in the present
case-control study. The demographic characteristics of the
control and CLI patient groups are summarized in Table 1.
CLI group patients were recruited at the Vascular Surgery
Department at Getafe University Hospital. A patient was
included if he met the following inclusion criteria: (1) had
symptoms of rest pain or ischemic distal ulcers (Rutherford’s
classiﬁcation, grade 4 and 5), (2) had objective signs of
distal ischemia—an ankle blood pressure of <60mmHg or
an ankle-brachial index of <0.5, and (3) was a candidate for
infrainguinal autologous vein bypass (TASC C or TASC D
lesions [5]) after undergoing angiography. Patients who were
decided to undergo endovascular revascularization were not
considered to be included.
Forty consecutive patients who met all these criteria
underwent below the knee autologous vein bypass, enabling
sampling of skin in each patient from the distal part of the
calf incision, were included. Twenty-three (57.5%) patients
experienced rest pain, and seventeen (42.5%) had ischaemic
ulcers aﬀecting the toe. None of the patients had a medically
documented history of cancer, arthritis, or other systemic
inﬂammation disease.
The preoperative arteriogram showed chronic total
occlusion of superﬁcial femoral artery in 29 out of 40
patients (72.5%). Nine (22.5%) of the patients had chronic
total occlusion of popliteal artery and proximal trifurcation
vessels,and2patients(5%)hadarecurrentstenosisaftertwo
endovascular interventions.
2.2. Control Subjects. 44 patients with chronic venous dis-
ease, with symptomatic C2 grade CEAP classiﬁcation [8],
who were undergoing elective crossectomy with stripping of
the great saphenous vein (GSV) served as control subjects.
Biopsies were collected from the skin close to the ankle. The
control subjects were screened to exclude patients with a
medical history of peripheral artery disease or those who
demonstrated objective signs of distal ischemia. All the
subjects in the control group were demonstrated to show an
ankle-brachial index of >0.9.
Controls with a medically history of cancer, arthritis, or
other systemic inﬂammation disease were excluded.
The study was performed according to institutional
guidelines and was approved by the Ethics Committee at the
Getafe University Hospital. Informed consent was obtained
from each patient and control subject before the inclusion in
accordance with principles of the Declaration of Helsinki.
2.3. Skin Biopsies. Samples were collected during operation.
Skin biopsies (2 × 2mm) were obtained from the distal part
of the calf incision in the CLI patients group and from the
ankle incision for GSV stripping in controls. Biopsies were
immediately introduced into RNAlater solution (Sigma, St.
Louis, MO, USA), stored for 24h at +4◦C, and then frozen to
−80◦C until processing.
2.4. VEGF Gene Expression. The samples were later thawed
andhomogenisedusingaMagNALyserelectrichomogeniser
(Roche, Basel, Switzerland). The RNA was obtained using
the commercial RNeasy Fibrous Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
The amount of puriﬁed RNA was determined using
spectrophotometry at 260nm in a Nanodrop analyser (ND-
100; Nanodrop Technologies, Wilmington, DE, USA). The
purity was veriﬁed according to the ratio of 260/280nm
measurements, such that values between 1.8 and 2.1 indi-
cated that the quality of the RNA obtained was optimal
and suitable for the quantitative real-time polymerase chain
reaction (qRT-PCR).
The VEGF gene expression was analysed using qRT-
PCR (Real Time PCR 7500 Fast. Version 2.0, Applied Bi-
osystems, Carlsbad, CA, USA). For the qRT-PCR study,
1µg of total RNA was reverse transcribed to complemen-
tary DNA (cDNA) using the commercial High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA, USA). Afterwards, 30ng of cDNA was used
as a mould for the real-time PCR in a ﬁnal volume
of 12µL which contained TaqMan Master Mix Universal
Fast (2x) plus the speciﬁc TaqMan (20x) test for the
gene studied. Ampliﬁcation was for 35 cycles of 94◦Cf o r
45s, 58◦C for 45s, and 72◦C for 60s. The gene studied
was VEGF (Hs009055 m1) using the following primers:
forward 5 -TCAAGGACAGAAGAGACTATAAAATTTGC-3 
and reverse 5 -ACTCCAAACTCCTTCCCCACAT-3 .T h eInternational Journal of Vascular Medicine 3
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Figure 1: Comparison of the VEGF gene expression for the skin
tissue between the CLI group and the control group using the
ΔΔCT method. Error bars express the RQ values of 95% conﬁdence
interval. ∗means statistical signiﬁcance.
18S gene of ribosomal RNA (Hs99999901 m1) with the fol-
lowing primers: forward 5 -GTAACCCGTTGAACCCCATT-
3  and reverse 5 -CCATCCAATCGGTAGTAGCG-3  and
the house-keeping Cyclophilin gene with primers: for-
ward 5 -AATGCTGGACCAAACACAAA-3  and reverse 5 -
CCTTCTTTCACCTTCCCAAA-3  were used as an endoge-
nous control.
The relative quantiﬁcation of the VEGF gene expression
was performed using the ΔΔCT comparative method [9].
The results were standardised to the content in the endoge-
nouscontrol.TheprogramcalculatestheΔCtsandtheΔΔCT
with the formulas below:
ΔCt = Ct Mean (18S) −Ct Mean

Target

,
ΔΔCt = ΔCt −ΔCt Mean,
Gene expression level = 2
−DDCt.
(1)
2.5. Statistical Analysis. The Kolmogorov-Smirnov test was
used to assess the normality of the distribution of the
variables. Comparisons of the VEGF expression were made
between the 2 groups using the Mann-Whitney U test for
independentvariables.Allcalculationswereperformedusing
the SPSS program version 15.0, the results were expressed as
mean ± standard deviation, and a P value < 0.05 in two-
tailed analysis was considered statistically signiﬁcant.
3. Results
Figure 1 shows the data for the VEGF gene expression ob-
tained using the ΔΔCT method after quantitative real-
time PCR reaction analysis. This method doubly normalizes
quantitative results of the analysis of gene expression by
the control genes (18S and cyclophilin), and the tissue was
having lower expression of VEGF.
It was shown that VEGF gene was absolutely overex-
pressed in CLI patient skin compared with cyclophilin gene
expression. Cyclophilin is a cyclosporine A cytosolic receptor
which is ubiquitously expressed and constantly in the cytosol
of all eukaryotic cells and tissues in which it was used
as house-keeping gene positive control to demonstrate the
relative quantiﬁcation expression of VEGF in the studied
tissues.
An analysis of the relative quantiﬁcation (RQ) values
using the ΔΔCT method was performed for skin tissue
between the CLI group and the control group. The results
revealed a signiﬁcant diﬀerence in the skin VEGF expression
between the two groups. Higher transcription of VEGF gene
in the CLI group than in the control group was found (1.3 ±
0.1v e r s u s1 ,P = 0.04).
4. Discussion
Hypoxia, a key in the origin of the etiopathological mech-
anisms of CLI, is a demonstrated stimulus for VEGF
production. The knowledge of the mechanisms of VEGF
regulation in CLI is crucial to understand the results arose
from new therapeutic angiogenesis approach. The present
study has reported that VEGF gene expression was greater
in ischaemic skin of CLI patients than in healthy skin
of non-arteriosclerotic patients. This data indicate that
the atherosclerotic status of CLI cause a higher hypoxia
environment which increases VEGF gene expression.
The data we have found of VEGF overexpression in is-
chaemic skin are consistent with the result previously
obtained in animal models of peripheral ischemia [10].
Also, this is in agreement with the results of Choksy et
al., who showed an elevation of VEGF expression at distal
sites in the ischaemic limbs [11]. Nevertheless, these data
diﬀer from those described by Palmer-Kazen et al. [12]w h o
found no association between VEGF concentrations and the
ischemic tissue area of the leg in patients with CLI. These
inconsistenciesmaybeexplainedbydiﬀerencesinthekindof
tissue analyzed, the product assessed, and the methods used
to determine the expression of VEGF. Palmer-Kazen et al.
measured the protein concentration of VEGF in biopsies of
muscleandskintissuesfromcalfandthighbyusingenzyme-
linked immunoassay whereas, in our study, the expression of
VEGF gene was determined by mRNA analysis using reliable
quantitative real-time polymerase chain reaction.
Otherwise, our results support the hypothesis that
ischemia-induced inﬂammation initiates local growth factor
production. In fact, recent data suggest that the inﬂam-
mation and the VEGF pathways may be related [13]. CRP
has been demonstrated to increase VEGF expression in
monocytic cells suggesting that CRP could play a role in
the angiogenesis process. It is plausible that CLI courses
with episodes of hypoxia in which a sharper state of
inﬂammation could be the cause of maintained VEGF
production. Moreover, VEGF has been detected in higher
levels in serum from patients with CLI than in patients with
intermittent claudication [7]. The origin of this circulating
VEGFcouldhypotheticallybethatbesidearterialendothelial
cells, others tissues from the chronically ischemic limb as the
skin, which is subject to a maintained hypoxia. The present
study has proven that VEGF gene expression is greater in
ischaemicskinthaninhealthyskin,observationthatsuggests4 International Journal of Vascular Medicine
that skin in the ischemic leg may be a possible source of this
protein.
In addition, our data indicate that the mechanisms for
VEGF upregulation in CLI remain intact. These data may
question the rationale of VEGF gene therapy.
Nonetheless, the present study has some limitations.
First, the diﬀerence in the gene expression between groups,
although signiﬁcant, is not high. These data would be
stronger if protein quantitative concentration in the tissues
samples was assessed. However, we believe this determi-
nation could mess the results and confuse the interpreta-
tion of these. This assessment should evaluate the protein
expression, in parallel to RNA expression. Still, the protein
assessment only would had measured the concentration of
VEGF in the tissue sample whatever its source. Meanwhile,
the objective of this study was, besides, to determine the
potential origin of the expression of the VEGF.
Second, the samples of the skin biopsies of the patients
group were not obtained from the most ischaemic skin
area in these patients. Distal part of the calf incision of the
autologous bypass procedure in CLI patients was used as a
surrogate of the most ischemic skin area by ethical concerns.
To collect a skin sample from a more distal area of the CLI
patient legs could have irreversibly damages and increased
exposure to amputation to patient limbs. Nevertheless, the
study beneﬁted from the homogeneity in the area whence all
the samples in the CLI group were obtained, avoiding in this
way the potential bias which we could have incurred if the
samples came from diﬀerent skin areas.
In conclusion, this study demonstrates an elevated VEGF
expression in the limb ischaemic skin in patients with
CLI. These data support that the mechanism for VEGF
upregulation in hypoxia environment is intact and acts
appropriately in the ischaemic limbs frompatients with CLI.
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